Shares of Novocure Ltd (NASDAQ:NVCR) have earned a consensus rating of “Buy” from the seven research firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $28.00.

Several analysts have issued reports on the stock. Mizuho reissued a “buy” rating and issued a $32.00 price objective on shares of Novocure in a research note on Wednesday. BidaskClub raised shares of Novocure from a “buy” rating to a “strong-buy” rating in a research note on Friday, May 25th. ValuEngine raised shares of Novocure from a “hold” rating to a “buy” rating in a research note on Wednesday, May 2nd. Zacks Investment Research downgraded shares of Novocure from a “buy” rating to a “hold” rating in a research note on Tuesday, May 1st. Finally, Wedbush raised their price objective on shares of Novocure from $29.00 to $33.00 and gave the stock an “outperform” rating in a research note on Friday, April 27th.

In other news, CFO Wilhelmus Cm Groenhuysen sold 9,393 shares of Novocure stock in a transaction that occurred on Friday, May 11th. The shares were sold at an average price of $30.01, for a total transaction of $281,883.93. Following the completion of the sale, the chief financial officer now owns 201,898 shares of the company’s stock, valued at $6,058,958.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CTO Yoram Palti sold 30,000 shares of Novocure stock in a transaction that occurred on Thursday, March 29th. The shares were sold at an average price of $21.67, for a total transaction of $650,100.00. The disclosure for this sale can be found here. In the last three months, insiders sold 1,103,798 shares of company stock valued at $30,396,645. 15.30% of the stock is owned by insiders.

Several institutional investors have recently bought and sold shares of NVCR. Stratos Wealth Partners LTD. purchased a new stake in shares of Novocure in the 1st quarter valued at approximately $109,000. UBS Group AG boosted its position in shares of Novocure by 379.2% in the first quarter. UBS Group AG now owns 9,809 shares of the medical equipment provider’s stock valued at $214,000 after acquiring an additional 7,762 shares during the period. Two Sigma Advisers LP bought a new stake in shares of Novocure in the fourth quarter valued at approximately $211,000. Elkfork Partners LLC bought a new stake in shares of Novocure in the fourth quarter valued at approximately $225,000. Finally, Lazard Asset Management LLC bought a new stake in shares of Novocure in the fourth quarter valued at approximately $271,000. 47.65% of the stock is owned by hedge funds and other institutional investors.

Shares of Novocure traded down $0.15, reaching $31.80, during trading on Monday, MarketBeat.com reports. The company’s stock had a trading volume of 5,974 shares, compared to its average volume of 916,079. The company has a current ratio of 6.32, a quick ratio of 5.87 and a debt-to-equity ratio of 1.41. Novocure has a 12 month low of $14.55 and a 12 month high of $32.03. The company has a market cap of $2.74 billion, a price-to-earnings ratio of -45.36 and a beta of 3.13.

Novocure (NASDAQ:NVCR) last announced its quarterly earnings results on Thursday, April 26th. The medical equipment provider reported ($0.23) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.10). The business had revenue of $52.13 million during the quarter, compared to the consensus estimate of $57.13 million. Novocure had a negative net margin of 33.12% and a negative return on equity of 56.70%. equities analysts forecast that Novocure will post -0.68 EPS for the current year.

Novocure Company Profile

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline.

Receive News & Ratings for Novocure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novocure and related companies with MarketBeat.com's FREE daily email newsletter.